James Cullem
Plus aucun poste en cours
Fortune : - $ au 31/03/2024
Profil
James G.
Cullem formerly worked at Allarity Therapeutics A, as Chief Executive Officer & Director from 2022 to 2023, Allarity Therapeutics, Inc., as CEO, Director & Chief Business Officer from 2022 to 2023, and Oncology Venture Sweden AB, as Vice President-Corporate Development.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 21/02/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Anciens postes connus de James Cullem
| Sociétés | Poste | Fin |
|---|---|---|
Allarity Therapeutics A/S
 Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | Chief Executive Officer | 08/12/2023 |
| ALLARITY THERAPEUTICS, INC. | Chief Executive Officer | 08/12/2023 |
Oncology Venture Sweden AB
 Oncology Venture Sweden AB BiotechnologyHealth Technology Oncology Venture Sweden AB engages in research and development of anti-cancer drugs through its subsidiary Oncology Ventures ApS. It focuses on diagnostics and development of medicinal products for treatment of cancer. The company was founded by Peter Buhl Jensen, Steen Meier Knudsen, Nils Aage Brünner, and Ulla Hald Buhl on June 4, 2015 and is headquartered in Hørsholm, Denmark. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ALLARITY THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Oncology Venture Sweden AB
Oncology Venture Sweden AB BiotechnologyHealth Technology Oncology Venture Sweden AB engages in research and development of anti-cancer drugs through its subsidiary Oncology Ventures ApS. It focuses on diagnostics and development of medicinal products for treatment of cancer. The company was founded by Peter Buhl Jensen, Steen Meier Knudsen, Nils Aage Brünner, and Ulla Hald Buhl on June 4, 2015 and is headquartered in Hørsholm, Denmark. | Health Technology |
Allarity Therapeutics A/S
Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | Health Technology |
